[go: up one dir, main page]

WO2007095688A1 - Méthodes d'augmentation du nombre de cellules en circulation - Google Patents

Méthodes d'augmentation du nombre de cellules en circulation Download PDF

Info

Publication number
WO2007095688A1
WO2007095688A1 PCT/AU2007/000209 AU2007000209W WO2007095688A1 WO 2007095688 A1 WO2007095688 A1 WO 2007095688A1 AU 2007000209 W AU2007000209 W AU 2007000209W WO 2007095688 A1 WO2007095688 A1 WO 2007095688A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
progenitor cells
group
composition
cell
Prior art date
Application number
PCT/AU2007/000209
Other languages
English (en)
Inventor
Christopher Richard Parish
Craig Geoffrey Freeman
Ljubov Simson
Kellie Johnston
Original Assignee
The Australian National University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006900910A external-priority patent/AU2006900910A0/en
Application filed by The Australian National University filed Critical The Australian National University
Publication of WO2007095688A1 publication Critical patent/WO2007095688A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to methods for increasing the number of circulating cells. More particularly, the invention relates to methods for increasing the number of circulating stem cells and leukocytes using anionic glycan mimetics.
  • PBSC Peripheral blood stem cells
  • Mobilisation into the peripheral blood is currently achieved with chemotherapy (eg cyclophosphamide), or by administration of expensive haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF), which requires days to achieve peak circulating HSC numbers, as well as short-lived IL-8 therapy which can act in minutes, but its effect is short lived.
  • haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF)
  • G-CSF granulocyte colony-stimulating factor
  • GM-CSF granulocyte macrophage colony-stimulating factor
  • Mature leukocytes and PBCs can be mobilised from the bone marrow into the circulation by the addition of sulfated polysaccharides, such as heparin and fucoidin and the sulfated oligosaccharide dextran sulfate.
  • sulfated polysaccharides such as heparin and fucoidin
  • each of these compounds can also act to prevent entry of the cells into tissues through inhibition of initial selectin-adhesion molecule binding to the endothelium and activity of extracellular matrix (ECM)- degrading enzymes preventing migration through the endothelium and ECM.
  • ECM extracellular matrix
  • the present inventors have discovered that low molecular weight anionic glycan mimetics induce a sustained release of circulating cells, such as mature leukocytes and HSCs, both systemically and locally. Additionally, the present inventors have discovered that these compounds do not prevent trafficking of circulating cells from the peripheral blood.
  • the cells may be stem cells including hematopoietic stem cells, mesenchymal stem cells, bone and osteoclast stem cells, hepatic and hepatic endothelial stem cells, myogenic stem cells, endothelial stem cells, epithelial stem cells, leukocytes, platelets and erythrocytes.
  • the hematopoietic stem cells may be selected from the group consisting of: lymphoid (B cell, T cell and dendritic cell) progenitor cells, myeloid (basophilic, eosinophilic, neutrophilic, monocytic, mast cell, macrophage and dendritic cell) progenitor cells, platelet progenitor cells including megakaryocytes and erythroid progenitor cells including erythroblasts.
  • lymphoid B cell, T cell and dendritic cell
  • myeloid basic, eosinophilic, neutrophilic, monocytic, mast cell, macrophage and dendritic cell
  • platelet progenitor cells including megakaryocytes
  • erythroid progenitor cells including erythroblasts.
  • the low molecular weight anionic glycan mimetic may be selected from the group consisting of: low molecular weight heparan sulfate mimetics, low molecular weight glycosaminoglycan mimetics, monosaccharides, disaccharides, oligosaccharides, cyclic oligosaccharides (for example cyclodextrins), cyclitols, arylene ureas, pseudo sugars, and mixtures thereof, each of which may possess one or more anionic residues.
  • the low molecular weight anionic glycan mimetic comprises one or more sulfate, phosphate or carboxylate groups.
  • a method for mobilising mature cells in a subject comprising administration to the subject of an effective amount of a low molecular weight anionic glycan mimetic, or a pharmaceutically acceptable salt thereof.
  • the mature cells may be selected from the group consisting of: lymphocytes, leukocytes, platelets and erythrocytes.
  • the lymphocytes may be selected from the group consisting of: T cells, natural killer cells, B cells and natural killer T cells.
  • the leukocytes may be selected from the group consisting of: neutrophils, basophils, monocytes, eosinophils, mast cells, dendritic cells, megakaryocytes and macrophages.
  • the present invention provides a method for mobilising stem cells in a subject, said method comprising administration to the subject of an effective amount of a low molecular weight anionic glycan mimetic or a pharmaceutically acceptable salt thereof.
  • the present invention provides a method for the treatment of a condition in a subject where a stem cell transplant is required, said method comprising administration to the subject of a therapeutically effective amount of a low molecular weight anionic glycan mimetic, or a pharmaceutically acceptable salt thereof.
  • the condition may be a haematological disease, an immunologic disease or a neoplastic disease.
  • the condition may be selected from the group consisting of: leukemia and lymphoma, acute lymphoblastic leukemia, acute myoblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, multiple myeloma, non-Hodgkin's lymphoma, childhood brain tumors, neuroblastoma, inherited blood disorders such as aplastic anaemia, beta-thalassemia, globoid cell leukodystrophy, X-linked lymphoproliferative syndrome, severe combined immunodeficiency syndrome, inherited inborn errors of metabolism that are treated with bone marrow transplants such as Hunter's syndrome, Hurler's syndrome, fucosidosis, Lesch Nyhan syndrome, haematopoietic stem cell rescue in cancer therapy, Graft-versus-host treatment of cancer, systemic lupus erythematosus, cardiovascular disease requiring myocardial regeneration using mesenchymal stem cell transplantation, muscle degenerative diseases requiring myogenic regeneration such
  • the hematopoietic stem cell may be selected from the group consisting of: lymphoid (B cell, T cell and dendritic cell) progenitor cells, myeloid (basophilic, eosinophilic, neutrophilic, monocytic, mast cell, macrophage and dendritic cell) progenitor cells, platelet progenitor cells including megakaryocytes and erythroid progenitor cells including erythroblasts.
  • lymphoid B cell, T cell and dendritic cell
  • myeloid basic, eosinophilic, neutrophilic, monocytic, mast cell, macrophage and dendritic cell
  • platelet progenitor cells including megakaryocytes
  • erythroid progenitor cells including erythroblasts.
  • the stem cell may be a megakaryocyte, and the condition may be selected from the group consisting of: drug- induced (e.g. heparin) thrombocytopenia, idiopathic thrombocytopenia purpura (ITP), Glanzmann thrombasthenia, Bernard-Soulier syndrome, Platelet-type von Willebrand disease, Hermansky-Pudlak and Chediak-Higashi syndromes, and defective platelet procoagulant activity (Scott syndrome).
  • drug- induced e.g. heparin
  • ITP idiopathic thrombocytopenia purpura
  • Glanzmann thrombasthenia Glanzmann thrombasthenia
  • Bernard-Soulier syndrome Bernard-Soulier syndrome
  • Platelet-type von Willebrand disease Hermansky-Pudlak and Chediak-Higashi syndromes
  • defective platelet procoagulant activity Scott syndrome
  • compositions for mobilisation of cells capable of circulating around the body of a subj ect comprising a low molecular weight anionic glycan mimetic, or a pharmaceutically acceptable salt thereof, and an agent, wherein the agent is capable of mobilisation of cells capable of circulating around the body of the subject.
  • Combinations of the low molecular weight anionic glycan mimetic and the agent may be synergistic in terms of their ability to mobilise cells capable of circulating.
  • the agent may be selected from the group consisting of: G-CSF, GM-CSF, IL-8, AMD-3100 and chemotherapeutic drugs, for example, methotrextrate, docetaxel, paclitaxel, epirubicin, mitoguazone, amifostine, adriamycin, taxol, fluorouracil, melphalan, cisplatin, alpha interferon, COMP (cyclophosphamide, vincristine, methotrexate and prednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PROMACE/MOPP (prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, taxol, etoposide/mechlorethamine, vincristine, predn
  • chemotherapeutic agents include alkylating agents such as nitrogen mustards including mechlorethamine, melphan, chlorambucil, cyclophosphamide and ifosfamide; nitrosoureas including carmustine, lomustine, semustine and streptozocin; alkyl sulfonates including busulfan; triazines including dacarbazine; ethylenimines including thiotepa and hexamethylmelamine; folic acid analogues including methotrexate; pyrimidine analogues including 5-fluorouracil, cytosine arabinoside; purine analogues including 6- mercaptopurine and 6-thioguanine; antitumour antibiotics including actinomycin D; the anthracyclines including doxorubicin, bleomycin, mitomycin C and methramycin; hormones and hormone antagonists including tamoxifen and corticosteroids and mis
  • one or more of the mobilised cells may enter into a tissue.
  • alkyl includes within its meaning monovalent straight chain or branched chain saturated hydrocarbon radicals having from 1 to 10 carbon atoms, eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
  • alkyl includes, but is not limited to, methyl, ethyl, 1 -propyl, isopropyl, 1 -butyl, 2-butyl, isobutyl, tert-butyl, amyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, pentyl, isopentyl, hexyl, 4-methylpentyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 1,2,2- trimethylpropyl, 1,1,2-trimethylpropyl, 2-ethylpenty
  • alkenyl includes within its meaning monovalent straight chain or branched hydrocarbon radicals having at least one double bond, and having from 2 to 10 carbon atoms, e.g. 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms.
  • alkenyl includes, but is not limited to vinyl, propenyl, 2-methylbutenyl and hexenyl.
  • alkoxy refers to o-alkyl, where alkyl is as defined above.
  • halo includes within its meaning fiuoro, chloro, bromo and iodo.
  • aryl includes within its meaning monovalent, single, polynuclear, conjugated and fused aromatic hydrocarbon radicals, for example phenyl, naphthyl, anthracenyl, pyrenyl, phenanthracenyl.
  • heteroaryl includes within its meaning monovalent, single, polynuclear conjugated and fused aromatic radicals having 1 to 15 carbons wherein 1 to 6 atoms are hetero atoms selected from O, N and S.
  • arylene includes within its meaning divalent, single, polynuclear, conjugated and fused aromatic hydrocarbon radicals.
  • cyclitol includes within its meaning cycloalkanes comprising one hydroxyl group on each of three or more ring atoms.
  • nucleic acid includes within its meaning monosaccharide, disaccharide or oligosaccharide molecules in which one or more of the "saccharide” units do not comprise an oxygen atom.
  • administering and variations of that term including “administer” and “administration”, includes contacting, applying, delivering or providing a compound or composition of the invention to an organism by any appropriate means.
  • treatment refers to any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever.
  • the term "effective amount” includes within its meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide the desired effect.
  • the exact amount required will vary from subject to subject depending on factors such as the desired effect, the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "effective amount”. However, for any given case, an appropriate "effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
  • C21 refers to the product obtained following the reaction of lactobionic acid with pyridine-sulfur trioxide complex as described in Example 1.
  • low molecular weight anionic glycan mimetic refers to sugar or saccharide mimetics or analogues or sugar-like compounds having molecular weights less than about 5kDa.
  • ring-opened monosaccharide refers to the respective saccharide molecules wherein at least one ring is present in the open chain form.
  • ring-opened compound may be for example an alditol or a glycol split, or any other product of complete or partial oxidation and/or reduction of said monosaccharide, disaccharide or oligosaccharide arising from, for example, reactions as are known in the art such as sodium borohydride reduction.
  • the terms “mobilisation” and “mobilising” refer to the migration of cells from a position where the cells were initially localised or stored (for example in the bone marrow, tissues or lymph tissue) and into circulation.
  • the terms “progenitor cell” and “stem cell” are used interchangeably and should be understood to have the same meaning.
  • Figure 1 shows various routes of administration (intravenous, intranasal and intraperitoneal) used to monitor the comparative effects of C21 -induced eosinophilia.
  • Figure 2A shows a leukocyte profile in the peripheral blood following intravenous treatment with C21 (50 ⁇ g/mouse). Each cell type was measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 2B shows an eosinophil profile in the peripheral blood following intravenous treatment with C21 (50 ⁇ g/mouse). Eosinophils were measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 2C shows neutrophilia, eosinophilia and progenitor presence in blood smears following intravenous C21 treatment.
  • Figures 3 A, 3B and 3 C show leukocyte, eosinophil and neutrophil profiles in the peripheral blood respectively, following intravenous treatment with high dose (lmg/mouse) C21. Each cell type was measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 4A shows an eosinophil profile in peripheral blood over a period of 6 hours following treatment of mice with various sulfated oligosaccharide derivatives. Eosinophils were measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 4B shows a neutrophil profile in peripheral blood over a period of 6 hours following treatment of mice with various sulfated oligosaccharides. Neutrophils were measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 4C shows a leukocyte profile in peripheral blood following treatment of mice with various oligosaccharides after 0 hours. Each cell type was measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 4D shows a leukocyte profile in peripheral blood following treatment of mice with various oligosaccharides after 2 hours. Each cell type was measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 4E shows a leukocyte profile in peripheral blood following treatment of mice with various oligosaccharides after 6 hours. Each cell type was measured as a percentage of the total leukocyte population in the peripheral blood.
  • Figure 5 shows the induction of leukocytosis and SDF- l ⁇ release into the peripheral blood following administration of synthetically-made sulfated glycan mimetics (SSGMs).
  • SSGMs synthetically-made sulfated glycan mimetics
  • Figure 6 A shows the effect of maltopentaose sulfate (MPS), C21 and fucoidan treatment on leukocyte trafficking in the peripheral blood. Total leukocytes in peripheral blood were calculated by manual haemocytometer counts following methylene blue staining.
  • Figure 6B shows the effect of maltopentaose sulfate (MPS), C21 and fucoidan treatment on neutrophil trafficking in the peripheral blood. Total neutrophils in peripheral blood were calculated by comparing differential cell counts to total leukocyte counts.
  • Figure 6C shows the effect of maltopentaose sulfate (MPS), C21 and fucoidan treatment on EGFP+ cell trafficking in the peripheral blood.
  • MPS maltopentaose sulfate
  • C21 maltopentaose sulfate
  • fucoidan treatment on EGFP+ cell trafficking in the peripheral blood.
  • the percentage of total leukocytes found to be EGFP+ in peripheral blood was determined by FACS analysis.
  • Figure 6D shows the effect of maltopentaose sulfate (MPS), C21 and fucoidan treatment on EGFP+ cell trafficking in the spleen.
  • MPS maltopentaose sulfate
  • Figure 7A shows an optical biosensor analysis of the effect of sulfated oligosaccharides on the association between heparin and eotaxin, and identifies C21 as an inhibitor of eotaxin/heparin association.
  • Figure 7B shows the effect of SSGMs on eotaxin binding to immobilised heparin.
  • Figure 8A shows haematopoietic progenitor cell (HPC) mobilisation after treatment with cyclophosphamide +/- fucoidan, maltopentaose sulfate or C21.
  • Figure 8B shows a quantitative analysis of haematopoietic progenitor cell (HPC) mobilisation after treatment with cyclophosphamide +/- fucoidan, maltopentaose sulfate or C21, indicated by the percentage of Lin " c-Kit + cells in total peripheral blood.
  • HPC haematopoietic progenitor cell
  • Figure 9A shows haematopoietic stem cell (HSC) mobilisation after treatment with cyclophosphamide +/- fucoidan, maltopentaose sulfate or C21.
  • Figure 9B shows a quantitative analysis of haematopoietic stem cell (HSC) mobilisation after treatment with cyclophosphamide +/- fucoidan, maltopentaose sulfate or C21, indicated by the percentage of Lin " c-Kit + Sca + cells in total peripheral blood.
  • HSC haematopoietic stem cell
  • Figure 9C shows a quantitative analysis of haematopoietic stem cell (HSC) mobilisation after treatment with cyclophosphamide +/- fucoidan, maltopentaose sulfate or C21, indicated by the percentage of Lin " c-Kit + Sca + cells as a portion of total Lin " c-Kit+ cells in peripheral blood.
  • HSC haematopoietic stem cell
  • the present invention is directed to a method for mobilisation of cells that are capable of circulating around the body of a subject.
  • the method comprises administration to the subject of a low-molecular weight anionic glycan mimetic.
  • the low molecular weight anionic glycan mimetic may be selected from the group consisting of: a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide (for example a cyclodextrin), a cyclitol, an arylene urea comprising one or more anionic residues, a pseudo sugar, and mixtures thereof.
  • the monosaccharide is a sulfated monosaccharide
  • the disaccharide is a sulfated disaccharide
  • the oligosaccharide is a sulfated oligosaccharide.
  • the monosaccharide may be a ring-opened monosaccharide
  • the disaccharide may be a ring-opened disaccharide
  • the oligosaccharide may be a ring- opened oligosaccharide.
  • the low molecular weight anionic glycan mimetic is a monosaccharide, disaccharide, oligosaccharide, ring-opended monosaccharide, ring- opended disaccharide or ring-opended oligosaccharide having the following structural formula:
  • A-(B) a wherein a is an integer between 0 and 9;
  • A is selected from the group consisting of: a diose, a triose, a tetraose, a pentose, a hexose, a heptose, an octose and a nonose, and each independent B is selected from the group consisting of: a diose, a triose, a tetraose, a pentose, a hexose, a heptose, an octose and a nonose; wherein A and B, and where a is an integer of 2 or greater, B and B, linked via a group selected from: -O-(CH 2 ) X -O-, -O-, -OCH 2 -, -NH-, -S-, -NR(CH 2 ) x -Ar-(CH 2
  • R, Ri and R 2 are selected from the group consisting of: hydrogen, alkyl, aryl, heteroaryl and C(O)-alkyl; x is an integer between 0 and 10; wherein A and B may be substituted with a functional group selected from the group consisting of: alkyl, alkenyl, aryl, halo, heteroaryl, an amide derivative such as -
  • NHCOCH 3 - alkoxy such as -OCH 3 - , -O- and -OH-; and wherein said diose, triose, tetraose, pentose, hexose, heptose, octose and nonose may be sulfated, phosphorylated or carboxylated.
  • a and each B are independently selected from the group consisting of a pentose, a hexose and a heptose, and are linked via a group selected from: -O-(CH 2 ) X -O-, -O-, -OCH 2 -, -NR(CH 2 ) X - Ar-(CHz) x NR 1 -, -O(CH 2 ) X -Ar-
  • R, R 1 and R 2 are selected from the group consisting of: hydrogen, acetyl and alkyl, and x is an integer between 1 and 6.
  • the hexose may be selected from the group consisting of: glucose, galactose, mannose, fructose, fucose, and idose, and the pentose may be xylose.
  • the low molecular weight anionic glycan mimetic is a cyclitol having the following structural formula:
  • D is selected from the group consisting of: N, CH, O, S, or a linker selected from -CO- NH-G-NH-CO-, -NH-CO-G-CO-NH-, -NH-G-NH-, -O-G-O-;
  • G is selected from the group consisting of alkylene and arylene
  • R 3 is a A-, 5-, or 6- membered carbocyclic ring that is saturated or unsaturated, wherein the ring comprises at least one sulfate group, at least one carboxylate group or at least one phosphate group.
  • R 4 is selected from the group consisting of: a A-, 5-, or 6- membered carbocyclic ring that is saturated or unsaturated, wherein the ring comprises at least one sulfate group, at least one carboxylate group or at least one phosphate group, hydrogen, aryl and alkyl;
  • E is selected from the group consisting of: hydrogen, alkyl, aryl, -B-C(R 5 )(R 6 ) and acetate;
  • B is selected from the group consisting of: -(CH 2 ) X -, -CH 2 C 6 H 4 CH 2 -, -CH 2 CH(OH)CH 2 -,
  • B group may optionally comprise one or more sulfate groups, one or more carboxylate groups or one or more phosphate groups.
  • R 5 and R 6 are independently selected from the group consisting of: A-, 5-, or 6- membered carbocyclic ring that is saturated or unsaturated, hydrogen, aryl and alkyl, wherein R 5 and/or R 6 may comprise one or more sulfate groups, one or more carboxlyate groups or one or more phosphate groups, and x is an integer between O and 10.
  • B is selected from the group consisting of: -(CH 2 ) X -, wherein x is an integer between 2 and 10, CH 2 C 6 H 4 CH 2 and CH 2 CH(OSO 3 H)CH 2 .
  • R 3 , R 4 , R 5 and R 6 may be independently selected from the following: wherein T is independently selected from the group consisting of: SO 3 H, SO 3 " , COOH, COO " , OPO 3 H and OPO 3 -.
  • the low molecular weight anionic glycan mimetic is an arylene urea of the following formula:
  • each Y is independently selected from the group consisting of: SO 3 H, SO 3 " , hydrogen, alkyl, halo, phenyl, an amide derivative, -NHCOCH 3 , -O-, -OCH 3 , COOH, COO " , OPO 3 H and OPO 3 " .
  • each V is independently selected from the group consisting of: -(NHC(O)Ph) 2 -, (CH 2 ) U and phenyl; W is -NH-C(O)-NH-; u and z may independently of each other be an integer between O and 10.
  • the arylene urea may be suramin, or a salt thereof.
  • the glycosaminoglycan mimetic may be a sulfated cyclic oligosaccharide, wherein the oligosaccharide is cyclodextrin.
  • the low molecular weight anionic glycan mimetic is aprosulate.
  • Low molecular weight anionic glycan mimetics for use in the compositions and methods of the invention may be purchased or prepared by methods known to those skilled in the art.
  • Sulfated saccharide compounds used in the methods and compositions of the invention may be prepared by sulfation of a corresponding monosaccharide, disaccharide or oligosaccharide also by methods known to those skilled in the art.
  • the saccharide compound may be treated with a sulfating agent such as pyridine-sulfur trioxide complex in the presence of an appropriate solvent as follows:
  • the low molecular anionic glycan mimetic may be a mixture of compounds obtained by reaction of a monosaccharide, disaccharide or oligosaccharide with pyridine-sulfur trioxide complex.
  • the low molecular weight anionic glycan mimetics may have one or more sulfate groups present. These sulfate groups may react with various bases to form salts.
  • the sulfated compounds are stable when in the form of a salt.
  • the sulfated compounds in a free form may be derived from a salt thereof by utilizing a cation-exchange resin such as Dowex 50W-X8.
  • a salt can be subjected to conventional ion-exchange to convert it into any one of various other desirable salts.
  • the oligosaccharides that are sulfated may be naturally occurring products, for example raffmose, stachyose or cyclodextrins.
  • the oligosaccharides may be prepared by enzymatic or chemical degradation of naturally occurring polysaccharides, followed by subsequent chemical modification.
  • Preferred low molecular weight anionic glycan mimetics useful in the methods and compositions of the invention include the following:
  • the second and third aspects of the invention respectively provide methods for mobilising leukocytes and stem cells in a subject.
  • the methods comprise administration to the subject of an effective amount of a low molecular weight anionic glycan mimetic, or a pharmaceutically acceptable salt thereof.
  • the anionic glycan mimetic may be as defined in the first aspect of the invention.
  • compounds capable of mobilising stem cells are useful in the treatment of conditions where a stem cell transplant is required.
  • the present invention is also useful in the treatment of conditions in a subject where a stem cell transplant is required.
  • the present invention provides a method for the treatment of a condition in a subject where a stem cell transplant is required, said method comprising administration of a therapeutically effective amount of a low molecular weight glycosaminoglycan mimetic, or a pharmaceutically acceptable salt thereof.
  • compositions for mobilisation of cells capable of circulating around the body of a subject comprising a low molecular weight glycosaminoglycan mimetic, or a pharmaceutically acceptable salt thereof, and an agent, wherein the agent is capable of mobilisation of cells capable of circulating around the body of the subject.
  • the anionic glycan mimetic and the agent may be administered simultaneously, sequentially or in succession. Where the anionic glycan mimetic and the agent are administered simultaneously, they may be present in a single composition which comprises both the glycosaminoglycan mimetic and the agent, or alternatively the anionic glycan mimetic and the agent may be present in separate compositions, one comprising the anionic glycan mimetic and one comprising the agent, which are administered simultaneously.
  • Examples of conditions which may be treated using a stem cell transplant may be selected from, but not limited to, the group consisting of: allogenic autologous leukemias, for example acute myelogenous, acute lymphoblastic, chronic myelogenous, chronic lymphocytic; lymphomas, for example Hodgkin's and non-Hodgkins; plasma cell disorders, for example, myeloma and amyloidosis; solid tumours, for example breast cancer, ovarian cancer, testicular cancer, renal cell cancer, brain tumours, neuroblastoma, Ewing's sarcoma; acquired bone marrow disorders, for example severe aplastic anemia, myelodysplastic syndrome, myeloproliferative disorders; congenital disorders, for example immunodeficiencies, Wiskott Aldrich's, Fanconi's anemia, Thalassemia, sickle cell anemia, osteoperosis and storage diseases; auto-immune diseases, for example scleroderma, rhe
  • compositions and routes of administration The low molecular weight anionic glycan mimetics may be present as pharmaceutically acceptable salts.
  • pharmaceutically acceptable salt it is meant those salts which, within the scope of sound medical judgement, are suitable for use in contact with tissues of humans and lower animals without the undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art.
  • the therapeutically effective amount of the compounds or agents disclosed herein for any particular subject will depend upon a variety of factors including: the disorder being treated and the severity of the disorder; activity of the compositions employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of sequestration of the compositions; the duration of the treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine.
  • an effective dosage of the low molecular weight anionic glycan mimetic is expected to be in the range of about O.OOOlmg to about lOOOmg per kg body weight per 24 hours; typically, about O.OOlmg to about 750mg per kg body weight per 24 hours; about O.Olmg to about 500mg per kg body weight per 24 hours; about O.lmg to about 500mg per kg body weight per 24 hours; about O.lmg to about 250mg per kg body weight per 24 hours; about l.Omg to about 250mg per kg body weight per 24 hours.
  • an effective dose range is expected to be in the range about l.Omg to about 200mg per kg body weight per 24 hours; about l.Omg to about lOOmg per kg body weight per 24 hours; about l.Omg to about 50mg per kg body weight per 24 hours; about l.Omg to about 25mg per kg body weight per 24 hours; about 5.0mg to about 50mg per kg body weight per 24 hours; about 5.0mg to about 20mg per kg body weight per 24 hours; about 5.0mg to about 15mg per kg body weight per 24 hours.
  • an effective dosage of a low molecular weight anionic glycan mimetic may be up to about 500mg/m 2 .
  • an effective dosage is expected to be in the range of about 25 to about 500mg/m 2 , preferably about 25 to about 350mg/m 2 , more preferably about 25 to about 300mg/m 2 , still more preferably about 25 to about 250mg/m 2 , even more preferably about 50 to about 250mg/m 2 , and still even more preferably about 75 to about 150mg/m 2 .
  • an effective dosage of the agent is expected to be in the range of about O.OOOlmg to about lOOOmg per kg body weight per 24 hours; typically, about O.OOlmg to about 750mg per kg body weight per 24 hours; about O.Olmg to about 500mg per kg body weight per 24 hours; about O.lmg to about 500mg per kg body weight per 24 hours; about 5 O.lmg to about 250mg per kg body weight per 24 hours; about l.Omg to about 250mg per kg body weight per 24 hours.
  • an effective dose range is expected to be in the range about l.Omg to about 200mg per kg body weight per 24 hours; about l.Omg to about lOOmg per kg body weight per 24 hours; about l.Omg to about 50mg per kg body weight per 24 hours; about l.Omg to about 25mg per kg body weight per 24 hours; about o 5.0mg to about 50mg per kg body weight per 24 hours; about 5.0mg to about 20mg per kg body weight per 24 hours; about 5.0mg to about 15mg per kg body weight per 24 hours.
  • an effective dosage of the agent may be up to about 500mg/m 2 .
  • an effective dosage is expected to be in the range of about 25 to about 500mg/m , preferably about 25 to about 350mg/m 2 , more preferably about 25 to about s 300mg/m 2 , still more preferably about 25 to about 250mg/m 2 , even more preferably about 50 to about 250mg/m 2 , and still even more preferably about 75 to about 150mg/m 2 .
  • compositions may be prepared according to methods which are known to those of ordinary skill in the art and accordingly may include a pharmaceutically acceptable carrier, diluent and/or adjuvant.
  • Convenient modes of administration include injection (subcutaneous, intravenous, o etc.), oral administration, intranasal, inhalation, transdermal application, topical creams or gels or powders, or rectal administration.
  • the formulation and/or compound may be coated with a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the therapeutic activity of the compound.
  • the compound may also be administered 5 parenterally or intraperitoneally.
  • Dispersions of compounds may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, pharmaceutical preparations may contain a preservative to prevent the growth of microorganisms.
  • Pharmaceutical compositions suitable for injection include sterile aqueous solutions
  • the composition is stable under the conditions of manufacture and storage and may include a preservative to stabilise the composition against the contaminating action of microorganisms such as bacteria and fungi.
  • the compound(s) may be administered orally, for example, with an inert diluent or an assimilable edible carrier.
  • the compound(s) and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into an individual's diet.
  • the compound(s) may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • such compositions and preparations may contain at least 1% by weight of active compound.
  • the percentage of the anionic glycan mimetic in pharmaceutical compositions and preparations may, of course, be varied and, for example, may conveniently range from about 2% to about 90%, about 5% to about 80%, about 10% to about 75%, about 15% to about 65%; about 20% to about 60%, about 25% to about 50%, about 30% to about 45%, or about 35% to about 45%, of the weight of the dosage unit.
  • the amount of compound in therapeutically useful compositions is such that a suitable dosage will be obtained.
  • pharmaceutically acceptable carrier is intended to include solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like.
  • Examples of pharmaceutically acceptable carriers or diluents are demineralised or distilled water; saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glyco
  • compositions according to the present invention It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a s predetermined quantity of compound(s) is calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the compound(s) may be formulated for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit.
  • a suitable pharmaceutically acceptable carrier in an acceptable dosage unit.
  • the dosages are determined by Q reference to the usual dose and manner of administration of the said ingredients, hi one embodiment, the carrier may be an orally administrable carrier.
  • Another form of a pharmaceutical composition is a dosage form formulated as enterically coated granules, tablets or capsules suitable for oral administration.
  • prodrug is an inactive form of a compound which is transformed in vivo to the active form.
  • Suitable prodrugs include esters, phosphonate esters etc, of the active form of the compound.
  • suitable carriers, diluents, excipients and adjuvants for oral use include peanut oil, liquid paraffin, sodium carboxymethylcellulose, methylcellulose, 0 sodium alginate, gum acacia, gum tragacanth, dextrose, sucrose, sorbitol, mannitol, gelatine and lecithin, hi addition these oral formulations may contain suitable flavouring and colourings agents.
  • the capsules When used in capsule form the capsules may be coated with compounds such as glyceryl monostearate or glyceryl distearate which delay disintegration.
  • the compound may be administered by injection.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by including various anti-bacterial and/or anti-fungal agents.
  • Suitable agents are well known to those skilled in the art and include, for example, parabens, chlorobutanol, phenol, benzyl alcohol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation.
  • dispersions are prepared by incorporating the analogue into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • Tablets, troches, pills, capsules and the like can also contain the following: a binder such as gum gragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
  • a binder such as gum gragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as
  • the dosage unit form When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar or both.
  • a syrup or elixir can contain the analogue, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed, hi addition, the analogue can be incorporated into sustained-release preparations and formulations.
  • the pharmaceutical compositions may further include a suitable buffer to minimise acid hydrolysis. Suitable buffer agent agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.
  • Single or multiple administrations of the pharmaceutical compositions according to the invention may be carried out.
  • One skilled in the art would be able, by routine experimentation, to determine effective, non-toxic dosage levels of the compound and/or composition of the invention and an administration pattern which would be suitable for treating the diseases and/or infections to which the compounds and compositions are applicable.
  • the optimal course of treatment such as the number of doses of the compound or composition of the invention given per day for a defined number of days, can be ascertained using convention course of treatment determination tests.
  • oligosaccharide e.g. the disaccharide lactobionic acid
  • 10 mL of anhydrous 7V,N-dimethyl formamide (DMF) Aldrich, WI, USA
  • pyridine-sulfur trioxide complex Aldrich, MO, USA
  • the solution was applied to a column (1.5 x 30 cm) of DOWEX 50W-X8 cation exchange resin (Na + form; Bio-Rad Laboratories, Hercules, CA).
  • DOWEX 50W-X8 cation exchange resin Na + form; Bio-Rad Laboratories, Hercules, CA.
  • the column was developed with water and each fraction tested for sulfate content by dimethylene blue assay (see below).
  • the sulfate-containing fractions were combined and dialysed in a 500 Da membrane sack (Spectropore) in 5 L of water at 4°C for 36 hours, with 4 changes of water.
  • the contents of the sack were lyophilised, and stored in powder form in a dessicator at 4 0 C. Using the above method, for some oligosaccharide reagents, no residue formed during the initial reaction.
  • mice Male BALB/c wild type mice were obtained from specific pathogen free facilities at the John Curtin School of Medical Research (JCSMR) and housed in approved containment facilities at the Australian National University (ANU). Mice were treated in accordance with ANU animal experimentation guidelines. Mice used in experiments were aged between 6 and 8 weeks.
  • Peripheral blood smears were taken from the tail vein. The blood smears were stained with May-Griinwald Geimsa stain and 200-300 cells were counted in each smear and differentiated on the basis of morphological characteristics to determine the percentage of cells in the leukocyte population of the peripheral blood.
  • Example 3 Measurement of the induction of eosinophilia using different routes of C-21 administration
  • mice were administered C21 (50 ⁇ g/mouse) once by intravenous, intraperitoneal, or intranasal administration.
  • mice were anaesthetised with isofluorane aerosol and 50 ⁇ L of C21 then applied dropwise to the nostrils.
  • Control mice were not administered C21.
  • Blood smears from the tail vein were taken 0, 12, 24, 36 and 48 hours post C21 challenge.
  • An eosinophil profile in the peripheral blood was generated according to methods outlined in Example 2.
  • Example 4 Leukocyte profiling in peripheral blood following C21 challenge
  • mice were administered C21 (50 ⁇ g/mouse) once by intravenous injection. Control mice were not administered C21. Blood smears from the tail vein were taken O 3 0.5, 2, 6 and 24 hours post C21 challenge. The leukocyte profile of the peripheral blood was investigated at each timepoint. Neutrophil levels were elevated from 18% to 52% by 0.5 hours post injection in the peripheral blood, accompanied by a corresponding decrease in the percentage of lymphocytes (Figure 2A).
  • Peripheral blood eosinophilia rose significantly from 2.5% to 9.5% by 0.5 hours post injection, remaining high at the 24hr completion of the experiment ( Figure 2B).
  • Example 5 Comparison of C21- or fucoidan-induced leukocytosis Mice were administered C21 or fucoidan (lmg/mouse or 50mg/kg) once by intravenous injection. Blood smears from the tail vein were taken 0, 0.5, 2, and 6 hours post C21 or fucoidan challenge. The leukocyte profile of the peripheral blood was compared following intravenous treatment with C21 or fucoidan at each timepoint.
  • a larger panel of SSGMs (lmg/mouse or 50mg/kg) were tested for their ability to induce eosinophilic and/or neutrophilic leukocytosis, and stromal derived factor- 1 alpha (SDF-l ⁇ ) release into the peripheral blood.
  • Blood smears from the tail vein were taken 0, 2 and 6 hours after intravenous injection, and the percentage of neutrophils and eosinophils were determined in peripheral blood.
  • C21, ClO and C22 were found to induce eosinophil leukocytosis ( Figure 4A, Figures 4C-4E, Figure 5), while many of the SSGMs tested induced neutrophilic leukocytosis ( Figure 4B, Figures 4C-4E, Figure 5).
  • SDF-l ⁇ Stromal cell-derived factor 1 alpha
  • Example 7 Trafficking of enhanced green fluorescent protein positive (EGFP + ) cells in response to challenge with SSGMs
  • mice Two million splenocytes from EGFP + transgenic mice (SPF facility, John Curtin School of Medical Research) were administered intravenously to mice, followed by a second intravenous injection of 100 ⁇ L of C21 (lOmg/mL), fucoidan (lOmg/mL), sulfated maltopentasaccharide (lOmg/mL) or saline. Blood and spleen samples were taken and processed 30 minutes post-injection, then analysed for EGFP + cells by FACS. Within 30 minutes, C21 and MPS treatment induced a general leukocytosis (Figure 6A) and neutrophilic leukocytosis ( Figure 6B).
  • Example 9 Haematopoietic progenitor cell and stem cell mobilisation following treatment with C21, maltopentaose sulfate (MPS) and fucoidan.
  • mice which strongly express stem cell antigen-1 (Sea) were injected on Day 0 with cyclophosphamide and blood samples were taken on days 0, 2, 4, 6 and 8. Six hours prior to sacrifice, mice were intravenously injected with 50mg/kg of the appropriate SSGM, or not injected and left as controls.
  • Sea stem cell antigen-1
  • HPC progenitor cells
  • HSC lineage negative (Lin " ) (where Lin ' cells are further defined as CD3 " , B220 “ , CDlIb ' ), stem cell factor receptor positive (c- kit + ), stem cell antigen- 1 positive (Sca + ) cells.
  • the effect of cyclophosphamide (Cyc) +/- SSGM treatment on Lin " c-Kit + Sca + cell numbers in the peripheral blood was evaluated by FACS in groups treated with cyclophosphamide (Cyc) alone ( Figure 9A), Cyc+Saline, Cyc+Fucoidan, Cyc+MPS, Cyc+C21 and untreated mice.
  • a pharmaceutical composition of the present invention for intramuscular injection could be prepared to contain 1-5 mL sterile buffered water, and 50 mg of low molecular weight anionic glycan mimetic.
  • a pharmaceutical composition for intravenous infusion may comprise 250 mL of sterile Ringer's solution, and 25 mg of a low molecular weight anionic glycan mimetic.
  • Capsule Composition A pharmaceutical composition of low molecular weight anionic glycan mimetic in the form of a capsule may be prepared by filling a standard two-piece hard gelatin capsule with 50 mg of a low molecular weight glycosaminoglycan mimetic, in powdered form, 100 mg of lactose, 35 mg of talc and 10 mg of magnesium stearate.
  • a pharmaceutical composition of this invention in a form suitable for administration by injection may be prepared by mixing 25 mg by weight of low molecular weight anionic glycan mimetic in 10% by volume propylene glycol and water. The solution is sterilised by filtration.
  • a lubricating agent such as polysorbate 85 or oleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de mobilisation de cellules capables de circuler dans l'organisme d'un sujet, ladite méthode comprenant l'administration au sujet d'une quantité active d'un composé glycane-mimétique anionique de faible poids molécu-laire, ou d'un sel de qualité pharmaceutique dudit composé.
PCT/AU2007/000209 2006-02-23 2007-02-23 Méthodes d'augmentation du nombre de cellules en circulation WO2007095688A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006900910 2006-02-23
AU2006900910A AU2006900910A0 (en) 2006-02-23 Methods for increasing the number of circulating cells

Publications (1)

Publication Number Publication Date
WO2007095688A1 true WO2007095688A1 (fr) 2007-08-30

Family

ID=38436861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2007/000209 WO2007095688A1 (fr) 2006-02-23 2007-02-23 Méthodes d'augmentation du nombre de cellules en circulation

Country Status (1)

Country Link
WO (1) WO2007095688A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037179A1 (fr) * 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Conjugués anioniques d’un métabolite bactérien glycosylé
US20130338097A1 (en) * 2010-12-01 2013-12-19 The Australian National University Histone inhibition
EP2721151A1 (fr) * 2011-06-20 2014-04-23 Mount Sinai School Of Medicine Thérapie anti-tnf contre les mucopolysaccharidoses et d'autres maladies lysosomiales
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
US9655953B2 (en) 2004-07-01 2017-05-23 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US9937246B2 (en) 2013-03-14 2018-04-10 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALKHATIB ET AL.: "Low molecular weight fucan prevents transplant coronapathy in rat cardiac allograft model", TRANSPLANT IMMUNOLOGY, vol. 16, 2006, pages 14 - 19 *
HIDALGO ET AL.: "The Integrin alphaMbeta2 anchors hematopoietic progenitors in the bone marrow during enforced mobilization", BLOOD, vol. 104, no. 4, 2004, pages 993 - 1001 *
SBAA-KETATA ET AL.: "Hyaluronan-derived oligosaccharide enhances SDF-1-dependent chemotactic effect on peripheral blood hematopoietic CD34+ cells", STEM CELLS, vol. 20, 2002, pages 585 - 587 *
SWEENEY ET AL.: "Increase in circulating SDF-1 after treatment with sulfated glycans", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 938, 2001, pages 48 - 53 *
SWEENEY ET AL.: "Mobilization of stem/progenitor cells by sulfated polysaccharides does not requires selectin pressure", PNAS, vol. 97, no. 12, 2000, pages 6544 - 6549 *
SWEENEY ET AL.: "Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells", BLOOD, vol. 99, no. 1, 2002, pages 44 - 51 *
VAN DER HAM ET AL.: "Mobilization of B and T lymphocytes and haemopoietic stem cells by polymethacrylic acid and dextran sulphate", CELLS AND TISSUE KINETICS, vol. 10, no. 4, 1977, pages 387 - 397 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655953B2 (en) 2004-07-01 2017-05-23 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
AU2009299118B2 (en) * 2008-10-03 2015-12-17 Glycan Biosciences Llc Anionic conjugates of glycosylated bacterial metabolite
US9346845B2 (en) 2008-10-03 2016-05-24 Glycan Biosciences Llc Anionic conjugates of glycosylated bacterial metabolite
CN102256989A (zh) * 2008-10-03 2011-11-23 聚糖生物科学私人有限公司 糖基化细菌代谢物的阴离子轭合物
US8791245B2 (en) 2008-10-03 2014-07-29 Glycan Bioscience LLC Anionic conjugates of glycosylated bacterial metabolite
CN102256989B (zh) * 2008-10-03 2016-01-06 聚糖生物科学有限责任公司 糖基化细菌代谢物的阴离子轭合物
WO2010037179A1 (fr) * 2008-10-03 2010-04-08 Glycan Biosciences Pty Ltd Conjugués anioniques d’un métabolite bactérien glycosylé
EP2646037A4 (fr) * 2010-12-01 2015-03-18 Univ Australian Inhibition d'histones
US9226939B2 (en) 2010-12-01 2016-01-05 The Australian National University Histone inhibition
US20130338097A1 (en) * 2010-12-01 2013-12-19 The Australian National University Histone inhibition
EP2721151A4 (fr) * 2011-06-20 2015-04-22 Sinai School Medicine Thérapie anti-tnf contre les mucopolysaccharidoses et d'autres maladies lysosomiales
US9155784B2 (en) 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
EP2721151A1 (fr) * 2011-06-20 2014-04-23 Mount Sinai School Of Medicine Thérapie anti-tnf contre les mucopolysaccharidoses et d'autres maladies lysosomiales
US10350277B2 (en) 2011-09-07 2019-07-16 Icahn School Of Medicine At Mount Sinai Ceramidase and cell differentiation
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
US10159724B2 (en) 2012-06-01 2018-12-25 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
US9937246B2 (en) 2013-03-14 2018-04-10 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
US10238721B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
US10918702B2 (en) 2013-03-14 2021-02-16 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them

Similar Documents

Publication Publication Date Title
WO2007095688A1 (fr) Méthodes d'augmentation du nombre de cellules en circulation
CN101010086B (zh) 作为免疫和自身免疫调节剂的神经酰胺衍生物
US9480702B2 (en) Use of chemically modified heparin derivates in sickle cell disease
US20140363507A1 (en) Dentric polyglycerol sulfates and sulfonates and their use for inflammatory diseases
JP6142039B2 (ja) ヒストン阻害
Cramer et al. β-Glucan enhances complement-mediated hematopoietic recovery after bone marrow injury
JP6900414B2 (ja) 酸化型β−１，４−グルクロン酸オリゴマーおよびその製造方法と使用
JP2006502129A (ja) 腎臓濾過および腎臓通過中のリソソーム分解に対して耐性を示す抗微生物性荷電ポリマー、その組成物および使用方法
US20110166078A1 (en) Oligosaccharide compounds for use in mobilising stem cells
Albanese et al. Glycosaminoglycan mimetics–induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: Structure/function insights
JP6339668B2 (ja) 細胞動員に使用するデキストラン硫酸
Generalov et al. Receptor basis of biological activity of polysaccharides
Rusnati et al. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis
WO2005027936A2 (fr) Traitement au moyen d'oligo-beta-(1,3)- glucanes et medicament utilises dans le cadre de ce traitement
Li et al. Low molecular-weight polyguluronate phosphate: An immunostimulant by activating splenocyte/macrophage in vitro and improving immune response in vivo
JP2016534078A (ja) 癌の処置に用いるための硫酸化多糖
TW201121965A (en) Use of a quinolone derivative containing 7-(4-aminomethyl-3-oxime)pyrrolidine group that is capable of inducing granulocyte colony stimulating factor for treatment of neutropenia and recovery of hematopoiesis
Becker Uproleselan sodium
Becker Uproleselan sodium. E-selectin antagonist, Treatment of acute myeloid leukemia
WO2023239711A1 (fr) Héparine chimiquement modifiée
Xu et al. Propylene glycol alginate sodium sulfate suppressed lung metastasis by blocking P-selectin to recruit CD4 regulatory T cells
JP2004002239A (ja) ＴＮＦ−α産生抑制剤
RU2442589C1 (ru) Способ стимуляции миелопоэза
Förster INFLUENCE OF GLYCOSAMINOGLYCANS ON NATURAL KILLER CELL ACTIVITY
Ramírez Patients Undergoing Allogeneic Cord Blood Transplantation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07701538

Country of ref document: EP

Kind code of ref document: A1